MELBOURNE, AUSTRALIA / ACCESSWIRE / May 29, 2015 / Propanc Health Group Corporation (PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced the Company briefed investors at the SeeThruEquity 4th Annual Microcap Investor Conference, held at the Convene Grand Central, Midtown Manhattan, New York, on Thursday, May 28th.
The Company discussed recent experimental activities and its current plans to progress their lead product PRP through the development process. Additionally, the company held multiple meetings during the week leading up to the conference with high net worth investors to discuss the capital needed to complete these important milestone activities.
“We have been very pleased with feedback received from investors regarding our drug development plans for PRP presented at the conference today,” said James Nathanielsz, Propanc’s Chief Executive Officer, “We appreciated their well informed questions and the opportunity to explain our thinking behind animal studies in progress through our research partners.”
The Company is presently conducting several animal studies for PRP and is expecting initial results mid-June, followed by additional data late July.
“The results from these studies will provide valuable information regarding the exposure of PRP in animals, as well as measuring its effectiveness against several tumor types implanted in mice,” said Professor Klaus Kutz, Propanc’s Chief Medical Officer, “It was a good opportunity to explain to investors our thinking behind the development of PRP, our anticipated timing, and how we intend to use this information to discuss with the regulatory authorities the structure of our planned animal safety toxicology studies to be completed prior to entering into human trials.”
We are a development stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic and colorectal cancer. Together with our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our leading products are variations upon our novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of our technology, we intend to submit our proenzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize it and any product(s) derived and/or to be derived therefrom.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In the future, we intend to development our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, please visit: www.propanc.com.
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company’s ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See Propanc’s most recent Quarterly Report on Form 10-Q and related 8K filings.